[1]
Costa Mdo C, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol 2012; 97(2): 239-57.
[2]
Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8(3): 221-8.
[3]
Lima M, Costa MC, Montiel R, et al. Population genetics of wild-type CAG repeats in the Machado-Joseph disease gene in Portugal. Hum Hered 2005; 60(3): 156-63.
[4]
Maciel P, Costa MC, Ferro A, et al. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 2001; 58(11): 1821-7.
[5]
Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 2003; 12(23): 3195-205.
[6]
Chai Y, Berke SS, Cohen RE, Paulson HL. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem 2004; 279(5): 3605-11.
[7]
Araujo J, Breuer P, Dieringer S, et al. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum Mol Genet 2011; 20(15): 2928-41.
[8]
Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138(2): 389-403.
[9]
Rodrigues AJ, Coppola G, Santos C, et al. Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J 2007; 21(4): 1126-36.
[10]
Schmitt I, Linden M, Khazneh H, et al. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 2007; 362(3): 734-9.
[11]
Bichelmeier U, Schmidt T, Hubener J, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 2007; 27(28): 7418-28.
[12]
Mueller T, Breuer P, Schmitt I, Walter J, Evert BO, Wullner U. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum Mol Genet 2009; 18(17): 3334-43.
[13]
Antony PM, Mantele S, Mollenkopf P, et al. Identification and functional dissection of localization signals within ataxin-3. Neurobiol Dis 2009; 36(2): 280-92.
[14]
Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho AL. Nucleocytoplasmic shuttling activity of ataxin-3. PLoS One 2009; 4(6): e5834.
[15]
Teixeira-Castro A, Ailion M, Jalles A, et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet 2011; 20(15): 2996-3009.
[16]
Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011; 480(7378): 543-6.
[17]
Simoes AT, Goncalves N, Koeppen A, et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 2012; 135(Pt 8): 2428-39.
[18]
Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J Mol Cell Biol 2010; 2(4): 180-91.
[19]
Alves S, Nascimento-Ferreira I, Auregan G, et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008; 3(10): e3341.
[20]
Alves S, Nascimento-Ferreira I, Dufour N, et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum Mol Genet 2010; 19(12): 2380-94.
[21]
Rodriguez-Lebron E, Costa M, Luna-Cancalon K, et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther 2013; 21(10): 1909-18.
[22]
Goodall EF, Heath PR, Bandmann O, Kirby J, Shaw PJ. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci 2013; 7: 178.
[23]
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
[24]
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
[25]
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115(7): 787-98.
[26]
Sonntag KC. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res 2010; 1338: 48-57.
[28]
Lee ST, Chu K, Im WS, et al. Altered microRNA regulation in Huntington’s disease models. Exp Neurol 2011; 227(1): 172-9.
[29]
Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 2008; 11(10): 1137-9.
[30]
Huang F, Zhang L, Long Z, et al. miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3. FEBS Lett 2014; 588(24): 4791-8.
[31]
Koscianska E, Krzyzosiak WJ. Current understanding of the role of microRNAs in spinocerebellar ataxias. Cerebellum Ataxias 2014; 1: 7.
[32]
Carmona V, Cunha-Santos J, Onofre I, et al. Unravelling endogenous microRNA system dysfunction as a new pathophysiological mechanism in Machado-Joseph disease. Mol Ther 2017; 25(4): 1038-55.
[33]
Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell 2006; 24(1): 157-63.
[34]
Stappert L, Borghese L, Roese-Koerner B, et al. MicroRNA-based promotion of human neuronal differentiation and subtype specification. PLoS One 2013; 8(3): e59011.
[35]
Saetrom P, Heale BS, Snove O Jr, Aagaard L, Alluin J, Rossi JJ. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res 2007; 35(7): 2333-42.
[36]
Denzler R, McGeary SE, Title AC, Agarwal V, Bartel DP, Stoffel M. Impact of microrna levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression. Mol Cell 2016; 64(3): 565-79.
[37]
Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579(26): 5911-22.
[38]
Landgraf P, Rusu M, Sheridan R. al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129(7): 1401-14.
[39]
Gurtner A, Falcone E, Garibaldi F, Piaggio G. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res 2016; 35: 45.
[40]
Onofre I, Mendonca N, Lopes S, et al. Fibroblasts of Machado Joseph disease patients reveal autophagy impairment. Sci Rep 2016; 6: 28220.
[41]
Shi Y, Huang F, Tang B, et al. MicroRNA profiling in the serums of SCA3/MJD patients. Int J Neurosci 2014; 124(2): 97-101.
[42]
Wu W, Yang J, Feng X, et al. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 2013; 12: 30.
[43]
Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50(2): 472-80.
[44]
Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105(35): 12885-90.
[45]
Zhang S, Chen H, Zhao X, et al. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene 2013; 32(2): 242-50.
[46]
Wang L, Pal S, Sif S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 2008; 28(20): 6262-77.
[47]
Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68(15): 6162-70.
[48]
Suh SS, Yoo JY, Nuovo GJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012; 109(14): 5316-21.
53
11
1